University of Hertfordshire

From the same journal

By the same authors

  • Hyun Kuk Kim
  • Udaya S. Tantry
  • Sidney C. Smith
  • Myung Ho Jeong
  • Seung Jung Park
  • Moo Hyun Kim
  • Do Sun Lim
  • Eun Seok Shin
  • Duk Woo Park
  • Yong Huo
  • Shao Liang Chen
  • Zheng Bo
  • Shinya Goto
  • Takeshi Kimura
  • Satoshi Yasuda
  • Wen Jone Chen
  • Mark Chan
  • Daniel Aradi
  • Tobias Geisler
  • Dirk Sibbing
  • Gregory Y.H. Lip
  • Dominick J. Angiolillo
  • Paul A. Gurbel
  • Young Hoon Jeong
View graph of relations
Original languageEnglish
JournalThrombosis and haemostasis
Early online date10 Nov 2020
DOIs
Publication statusE-pub ahead of print - 10 Nov 2020

Abstract

East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.

Notes

Publisher Copyright: © 2020 American Medical Association. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

ID: 24591916